A compelling case in MBC showcased dynamic changes in PD-L1 positive CTC proportions during combination immunotherapy (nivolumab/ipilimumab), highlighting the potential of integrating CTC analysis to advance personalized cancer treatment strategies [150]. Here, CD274 is linked to cancer.